Irinotecan + targeted therapy vs irinotecan
Irinotecan + targeted therapy showed no clear difference in overall survival compared with irinotecan (low certainty).
- Second‐line systemic therapy for metastatic colorectal cancer 2017 · Cochrane Headline outcomes onlyHR 0.99 [0.88, 1.1]2 studies · 1758 participantsLow